COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Rolf Jakobi

Dr. Rolf Jakobi

Scientific Review Officer


Division of Basic and Integrative Biological Sciences DBIB
Oncology 1 Basic Translational OBT
Study Section:
Tumor Progression and Metastasis TPM

Dr. Jakobi is the Scientific Review Officer for CSR’s Tumor Progression and Metastasis (TPM) Study Section.

He received a Ph. D. from the University of Kaiserslautern, Germany for studies on cloning and characterization of casein kinase 2 (CK-2) at the German Cancer Research Center in Heidelberg. His postdoctoral research and training at the German Cancer Research Center and the University of California, Riverside focused on protein phosphorylation and signal transduction. Dr. Jakobi served as assistant professor of Pharmacology and Toxicology at the Medical College of Wisconsin, Milwaukee and as associate professor of Biochemistry at the Kansas City University of Medicine and Biosciences. Dr. Jakobi’s research focused on the role of p21-activated kinase 2 (PAK-2) in cell growth and cell death and in breast cancer development and progression. In addition, he was involved in studies on the role of cyclooxygenase 2 (COX-2) in colon cancer cell adhesion, motility and invasion.